+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

CYP2D6*4 polymorphism is associated with statin-induced muscle effects

CYP2D6*4 polymorphism is associated with statin-induced muscle effects

Pharmacogenetics and Genomics 17(9): 695-707

Statin use is associated with a variety of overtly related muscle symptoms including muscle pain, myalgia, creatine kinase elevations without pain with myolysis and myositis (rhabdomyolysis), a potentially fatal side effect that led to the withdrawal of cerivastatin in 2001. Unintended drug response phenotypes have an impact on patient compliance and sometimes patient health and the assessment of risk on an individual basis could enhance therapeutic benefit. We therefore investigated whether common single nucleotide polymorphisms were associated with the expression of broadly grouped atorvastatin-induced muscle events in a case-control study (n=263 samples, n=388 SNPs). Of a number of associations identified in a discovery sample (51 atorvastatin-induced muscle and 55 normal) only those corresponding to the CYP2D6*4 allele were significantly associated in the sample (24 atorvastatin-induced muscle and 133 normal) (Discovery P=0.004, odds ratio=3.6; Validation P=0.036, odds ratio=2.7; total P=0.001, odds ratio=2.5). The frequency of the CYP2D6*4 allele was about 50% in atorvastatin-induced muscle patients but only 28% in controls, similar to that of other patient types (28.5%). The association was independent of various demographic variables and not explained by gross demographic, clinical or population-structure differences among cases and controls. Surprisingly, the CYP2D6*4 allele appeared similarly distributed among controls and patients expressing simvastatin-induced muscle events (n=169, frequency in case participants=49.2%, P=0.067, odds ratio=1.7). Our results suggest that the CYP2D6*4 allele is associated with broadly related muscle events caused by at least two structurally dissimilar HMG-CoA reductase inhibitors, and as such, may have implications for a better understanding of this statin-wide phenomena.

(PDF emailed within 0-6 h: $19.90)

Accession: 015193995

Download citation: RISBibTeXText

PMID: 17700359

DOI: 10.1097/FPC.0b013e328012d0a9

Related references

Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia. Current Medical Research and Opinion 30(2): 223-228, 2015

CYP2D6 polymorphism in a Gabonese population: Contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. British Journal of Clinical Pharmacology 47(1): 121-124, 1999

Statin therapy. Avoiding statin-related muscle side effects. Reviews in Cardiovascular Medicine 10(3): 180-181, 2009

Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6. Drug Metabolism and Drug Interactions 28(4): 209-216, 2014

Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. Journal of Toxicology and Environmental Health. Part B, Critical Reviews 12(5-6): 334-361, 2010

Genetic polymorphism of CYP2D6: Malaysian Indians have the highest frequency for CYP2D6*4 in Asia. European Journal of Clinical Pharmacology 57(8): 617-618, 2002

Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics 4(3): 154-158, 1994

C-1584G polymorphism is not the very SNP causing increased CYP2D6 activity of CYP2D6*41. Clinical Pharmacology & Therapeutics 75(2): P67, February, 2004

Severity of statin-induced adverse effects on muscle and associated conditions: data from the DAMA study. Expert Opinion on Drug Safety 15(12): 1583-1587, 2016

Red yeast rice may be a statin substitute. People who are statin-intolerant due to side effects of muscle pain may benefit from this ancient Asian dietary and medicinal staple. Dukemedicine Healthnews 15(9): 1-2, 2009

In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis and Rheumatism 55(4): 551-557, 2006

Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels. Drug Metabolism and Pharmacokinetics 31(2): 156-162, 2016

Forcibly increasing carbohydrate oxidation by pharmacological activation of the pyruvate dehydrogenase complex reduces statin mediated upregulation of FOXO gene targets and protects against statin-induced myopathy in rodent skeletal muscle. 2012